Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • From chick to bedside: Removing the Wnt barrier

  • Abnormal brain rhythms tied to problems with thinking in schizophrenia

  • Exposure to endocrine disruptors during pregnancy affects the brain two generations later, rat study shows

  • Autistic features linked to prenatal exposure to commonly found fire retardants, phthalates

  • Drug to control appetite could also fight anxiety

  • Human brains age less than previously thought

  • Neuroscientists perform important step towards cell therapy for diseases of the cerebral cortex

  • Why some brain cancers resist treatment

  • Mechanism behind most common form of inherited Alzheimer's disease revealed

  • Mental health soon after war-zone concussions predicts disability

  •